Entera Bio (ENTX) Competitors $2.10 -0.06 (-2.78%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ENTX vs. VALN, CCCC, FDMT, CMPS, IMMP, ACIU, LRMR, AMLX, LFCR, and ITOSShould you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Valneva (VALN), C4 Therapeutics (CCCC), 4D Molecular Therapeutics (FDMT), COMPASS Pathways (CMPS), Immutep (IMMP), AC Immune (ACIU), Larimar Therapeutics (LRMR), Amylyx Pharmaceuticals (AMLX), Lifecore Biomedical (LFCR), and iTeos Therapeutics (ITOS). These companies are all part of the "pharmaceutical products" industry. Entera Bio vs. Valneva C4 Therapeutics 4D Molecular Therapeutics COMPASS Pathways Immutep AC Immune Larimar Therapeutics Amylyx Pharmaceuticals Lifecore Biomedical iTeos Therapeutics Valneva (NASDAQ:VALN) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, community ranking, risk, earnings, profitability, media sentiment and valuation. Which has more volatility & risk, VALN or ENTX? Valneva has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Which has better valuation and earnings, VALN or ENTX? Entera Bio has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioValneva$158.54M2.04-$109.78M-$0.13-30.69Entera Bio$99K759.08-$8.89M-$0.26-8.08 Does the media refer more to VALN or ENTX? In the previous week, Valneva had 5 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for Valneva and 0 mentions for Entera Bio. Valneva's average media sentiment score of 0.33 beat Entera Bio's score of 0.00 indicating that Valneva is being referred to more favorably in the media. Company Overall Sentiment Valneva Neutral Entera Bio Neutral Does the MarketBeat Community prefer VALN or ENTX? Entera Bio received 147 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 67.55% of users gave Entera Bio an outperform vote while only 60.38% of users gave Valneva an outperform vote. CompanyUnderperformOutperformValnevaOutperform Votes3260.38% Underperform Votes2139.62% Entera BioOutperform Votes17967.55% Underperform Votes8632.45% Is VALN or ENTX more profitable? Entera Bio has a net margin of 0.00% compared to Valneva's net margin of -4.35%. Valneva's return on equity of -3.93% beat Entera Bio's return on equity.Company Net Margins Return on Equity Return on Assets Valneva-4.35% -3.93% -1.42% Entera Bio N/A -107.24%-92.29% Do institutionals and insiders believe in VALN or ENTX? 11.4% of Valneva shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 10.9% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer VALN or ENTX? Valneva presently has a consensus price target of $18.50, indicating a potential upside of 363.66%. Entera Bio has a consensus price target of $10.00, indicating a potential upside of 376.19%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryValneva beats Entera Bio on 9 of the 17 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get Entera Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTX vs. The Competition Export to ExcelMetricEntera BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.15M$2.94B$5.13B$9.08BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-8.0846.7391.4117.18Price / Sales759.08412.591,113.85116.83Price / CashN/A182.1042.7137.86Price / Book5.833.894.794.78Net Income-$8.89M-$42.21M$120.07M$225.60M7 Day Performance-2.78%-2.15%-1.91%-1.23%1 Month Performance29.63%4.20%11.46%3.36%1 Year Performance208.82%18.39%30.54%16.59% Entera Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTXEntera Bio1.4334 of 5 stars$2.10-2.8%$10.00+376.2%+195.8%$75.15M$99,000.00-8.0820VALNValneva2.1546 of 5 stars$3.84-2.3%$18.50+381.8%-62.2%$312M$165.52M-30.23700News CoverageHigh Trading VolumeCCCCC4 Therapeutics2.063 of 5 stars$4.31-1.6%$10.00+132.0%-9.2%$304.24M$33.67M-2.58150Analyst UpgradeNews CoveragePositive NewsFDMT4D Molecular Therapeutics2.5926 of 5 stars$6.58+1.2%$42.13+540.2%-66.9%$304.18M$17,000.00-2.28201Analyst ForecastCMPSCOMPASS Pathways2.8299 of 5 stars$4.36+3.3%$33.60+670.6%-47.3%$298.32MN/A-1.92120Positive NewsIMMPImmutep1.4184 of 5 stars$2.05-6.0%$8.50+314.6%-13.2%$298.19M$5.14M0.002,021ACIUAC Immune2.4745 of 5 stars$2.95flat$12.00+306.8%-33.8%$291.87M$16.48M-6.41140Positive NewsLRMRLarimar Therapeutics1.5678 of 5 stars$4.52-26.7%$20.43+352.0%+4.4%$288.42MN/A-3.5630Analyst RevisionNews CoveragePositive NewsGap DownHigh Trading VolumeAMLXAmylyx Pharmaceuticals4.2561 of 5 stars$4.17+1.2%$7.33+75.9%-70.7%$285.85M$196.49M-1.08200Short Interest ↓News CoveragePositive NewsLFCRLifecore Biomedical2.9037 of 5 stars$7.76+2.0%$10.00+28.9%+18.7%$285.78M$128.44M97.50690ITOSiTeos Therapeutics3.5018 of 5 stars$7.76+1.0%$25.25+225.4%-28.4%$283.50M$35M-2.4490Analyst Forecast Related Companies and Tools Related Companies Valneva Competitors C4 Therapeutics Competitors 4D Molecular Therapeutics Competitors COMPASS Pathways Competitors Immutep Competitors AC Immune Competitors Larimar Therapeutics Competitors Amylyx Pharmaceuticals Competitors Lifecore Biomedical Competitors iTeos Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ENTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entera Bio Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entera Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENTX Stock Alerts